Mastocytosis is a very common breast disease, and its incidence ranks first among all breast diseases. A survey was conducted and found that 33.34% of adult women have varying degrees of breast hyperplasia in health checkups; in breast specialist clinics, breast hyperplasia patients account for nearly 90%. With the development of the times, the enhancement of health awareness and the popularization of health education, people are becoming more and more knowledgeable about mastocytosis, but one thing cannot be denied, that is, some of these understandings are ambiguous or even wrong, which will undoubtedly have some negative impact on people’s attitudes and behaviors in the prevention and treatment of mastocytosis, which is not conducive to breast health, and it is necessary to clarify this. Mistake 1: Mastocytosis is a tumor Mastocytosis is formed due to degenerative and progressive changes in the structure of the ducts and lobules of the breast, so it is also called “poor breast structure”, and its occurrence, development and regression are greatly related to the level of estrogen in women. Normally, during each menstrual cycle, the ductal epithelium and interlobular fibrous tissues of the breast go through a process of tissue changes of proliferation and recovery. Under the stimulation of certain triggering factors, the estrogen level of the body may increase relatively or absolutely, which causes the proliferation of ductal epithelial cells and fibrous tissues in the premenstrual period to exceed the normal range, resulting in the failure to recover or incomplete recovery of the hyperplastic tissues that should be recovered, and over time, the accumulation of nodules or lumps will form. Pathological studies have confirmed that these nodules or lumps are mainly increased in number of cells and fibrous tissues without cytogenetic changes, and their biological properties are similar to normal cells. Therefore, breast hyperplasia and tumor are two completely different things, so there is no need to worry about it. Mistake 2: The more painful the breast, the more serious the breast hyperplasia Breast pain is the most common symptom of breast hyperplasia, and the typical pain usually has a cyclical feature consistent with menstruation, that is, the pain appears almost a week before menstruation and decreases or disappears after menstruation. In most cases, the pain is mild and tolerable, but it is rare that the pain is severe and can sometimes radiate to the armpits, neck and shoulders. Experts believe that the occurrence and severity of breast pain is related to the intensity of physical and chemical stimuli in the breast tissue and the individual’s tolerance of pain, and is not exactly parallel to the severity of breast enlargement, which is also the case in practice. Breast pain in adolescence, i.e., simple breast hyperplasia, is mainly manifested by periodic pain, and the objective pathological changes of breast hyperplasia are not obvious; while those with obvious pathological changes of breast adenopathy and cystic hyperplasia of the breast may not have obvious subjective discomfort due to the longer history of the disease and the adaptive transformation of the organism. Therefore, “the more painful the breast, the more serious the mastopexy.” This is a biased statement, and it is even more dangerous to use it as a basis for whether or not mastocytosis needs to be treated. Mistake 3: Mastocytosis is closely related to breast cancer The research on whether mastocytosis is cancerous has never stopped in the medical field, but so far there is not enough evidence to prove a clear relationship between mastocytosis and breast cancer. Since it is very difficult to make animal models of mastocytosis and there is no way to start animal experiments that are more illustrative, the existing studies have focused on historical review of the past medical history of breast cancer patients and long-term follow-up observation of mastocytosis patients. It has been found that about 2-3% of mastocytosis may become cancerous, and that patients with cystic hyperplasia have a 3-5 times greater chance of developing breast cancer than women in the same age group with non-cystic hyperplasia, but statistical analysis showed no significant difference between the two. Therefore, there is no scientific basis to say that “breast hyperplasia is closely related to breast cancer”. It is generally believed that breast hyperplasia is only one of the many risk factors for breast cancer. However, it is important to note that the chance of breast hyperplasia becoming breast cancer increases when it is accompanied by epithelial atypical hyperplasia, which is considered as precancerous lesion. In conclusion, mastocytosis is a benign disease that is neither inflammatory nor tumor, and the chance of cancer is not much greater than normal, as long as self-care is correct, treatment is timely and reasonable, and regular medical review is done, the prognosis is good.